Roche/GSK Preparing Boniva NDA For Once-Quarterly I.V. Formulation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche’s upcoming NDA for a long-acting injectable formulation of Boniva (ibandronate) will be the third regulatory submission for the as yet unlaunched osteoporosis agent.